Syndax looks to rebound from stinging late-stage failure, uncorking early data for next cancer drug up

A year ago, Syndax Pharmaceuticals suffered a major Phase III flop that forced it to forgo an FDA filing for its …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Syn­dax looks to re­bound from sting­ing late-stage fail­ure, un­cork­ing ear­ly da­ta for next can­cer drug up